Cargando…

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer

BACKGROUND: Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 inhibitor) in colorectal cancer (CRC), however single agent therapeutics are often limited by the development of resistance. METHODS: We compared the an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Cha Len, Cremona, Mattia, Farrelly, Angela, Workman, Julie A., Kennedy, Sean, Aslam, Razia, Carr, Aoife, Madden, Stephen, O’Neill, Brian, Hennessy, Bryan T., Toomey, Sinead
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281467/ https://www.ncbi.nlm.nih.gov/pubmed/37326340 http://dx.doi.org/10.1080/15384047.2023.2223388

Ejemplares similares

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
por: Aslan, Ozlem, et al.
Publicado: (2018)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
por: Cremona, Mattia, et al.
Publicado: (2022)

Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
por: Zhu, Lin, et al.
Publicado: (2022)

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
por: Kennedy, Sean P., et al.
Publicado: (2020)

CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
por: Lu, Janice
Publicado: (2015)

Glucose Metabolic Reprogramming of ER(+) Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib
por: Lorito, Nicla, et al.
Publicado: (2020)

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
por: Coté, Damien, et al.
Publicado: (2018)

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
por: Miettinen, Teemu P, et al.
Publicado: (2018)

Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27
por: Pennycook, Betheney R., et al.
Publicado: (2021)

Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor
por: Liu, Yahong, et al.
Publicado: (2023)

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
por: Mezynski, M. Janusz, et al.
Publicado: (2021)

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
por: Martin-Broto, Javier, et al.
Publicado: (2023)

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
por: Milewska, Malgorzata, et al.
Publicado: (2018)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
por: Saleh, Lubaid, et al.
Publicado: (2023)

CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
por: Qin, Qiong, et al.
Publicado: (2020)

Fusobacterium nucleatum: caution with interpreting historical patient sample cohort
por: Johnstone, Kate L. F., et al.
Publicado: (2021)

MEK blockade overcomes the limited activity of palbociclib in head and neck cancer
por: Fang, Zhenghuan, et al.
Publicado: (2020)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity
por: Bonuccelli, Gloria, et al.
Publicado: (2016)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
por: Bandiera, Carole, et al.
Publicado: (2023)

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer
por: Laha, Dipranjan, et al.
Publicado: (2022)

Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
por: Madden, Stephen F., et al.
Publicado: (2022)

CDK4/6 Inhibitor Palbociclib Amplifies the Radiosensitivity to Nasopharyngeal Carcinoma Cells via Mediating Apoptosis and Suppressing DNA Damage Repair
por: Xie, Xianhe, et al.
Publicado: (2019)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
por: Elster, Naomi, et al.
Publicado: (2018)

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
por: Fernandez, Marta Llaurado, et al.
Publicado: (2019)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d6pk4oc2g95cc5fmse5ibre4qc